BioRegenex Completes Seed Funding Round

After successfully completing its technology POC seed funding round BioRegenex has it's sights set on a series A to develop its technology platforms and advance its therapeutic programs towards the clinic

BioRegenex secures it's first official equity funding

BioRegenex Pty Ltd, an Australian based Bio-Engineering Technology Platform company closed a seed funding round of undisclosed amount.

Backers included business magnate Bill Moss the heavy weight ex director of Australia's Macquarie Bank, Agincourt Advisory a boutique healthcare & medical technologies investment advisory firm and other private investors.

BioRegenex is a bio-engineering technology company commercializing the development of next generation synthetic bio structures for muscle, nerve and tissue regeneration.

Its lead products are cell mediated myoregenerative muscle transplant constructs which take advantage of biological stem cell engineering combined with gene correction technologies and 3D bio-fabrication expertise to create implantable muscle therapeutics for neuromuscular conditions, oncology associated cachexia, sarcopenia (degenerative muscle loss associated with aging), sports medicine & major trauma (such as the very lucrative defence technologies market).

The company intends to use the funds to further develop its key platforms, scale-up R&D capabilities and facilitate strategic collaborations and partnerships to accelerate the development of its technologies & therapeutics programs.

© 2019 BioRegenex Pty Ltd